HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Neuroprotective and neurorestorative activities of a novel iron chelator-brain selective monoamine oxidase-A/monoamine oxidase-B inhibitor in animal models of Parkinson's disease and aging.

Abstract
Recently, we have designed and synthesized a novel multipotent, brain-permeable iron-chelating drug, VAR10303 (VAR), possessing both propargyl and monoamine oxidase (MAO) inhibitory moieties. The present study was undertaken to determine the multiple pharmacological activities of VAR in neurodegenerative preclinical models. We demonstrate that VAR affords iron chelating/iron-induced lipid-peroxidation inhibitory potency and brain selective MAO-A and MAO-B inhibitory effects, with only limited tyramine-cardiovascular potentiation of blood pressure. The results show that in 6-hydroxydopamine rat (neuroprotection) and in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse (neurorescue) Parkinson's disease models, VAR significantly attenuated the loss of striatal dopamine levels, markedly reduced dopamine turnover, and increased tyrosine-hydroxylase levels. Furthermore, chronic systemic treatment of aged rats with VAR improved cognitive behavior deficits and enhanced the expression levels of neurotrophic factors (e.g., brain-derived neurotrophic factor, glial cell-derived neurotrophic factor, and nerve growth factor), Bcl-2 family members and synaptic plasticity in the hippocampus. Our study indicates that the multitarget compound VAR exerted neuroprotective and neurorestorative effects in animal models of Parkinson's disease and aging, further suggesting that a drug that can regulate multiple brain targets could be an ideal treatment-strategy for age-associated neurodegenerative disorders.
AuthorsOrit Bar-Am, Tamar Amit, Lana Kupershmidt, Yuval Aluf, Danit Mechlovich, Hoda Kabha, Lena Danovitch, Vincent R Zurawski, Moussa B H Youdim, Orly Weinreb
JournalNeurobiology of aging (Neurobiol Aging) Vol. 36 Issue 3 Pg. 1529-42 (Mar 2015) ISSN: 1558-1497 [Electronic] United States
PMID25499799 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2015 Elsevier Inc. All rights reserved.
Chemical References
  • 5-(2-(methylprop-2-ynylamino)ethyl)quinolin-8-ol
  • Hydroxyquinolines
  • Iron Chelating Agents
  • Monoamine Oxidase Inhibitors
  • Nerve Growth Factors
  • Neuroprotective Agents
  • Monoamine Oxidase
  • Dopamine
Topics
  • Aging
  • Animals
  • Cognition
  • Disease Models, Animal
  • Dopamine (metabolism)
  • Hydroxyquinolines (pharmacology, therapeutic use)
  • Iron Chelating Agents (pharmacology, therapeutic use)
  • Male
  • Mice, Inbred C57BL
  • Molecular Targeted Therapy
  • Monoamine Oxidase
  • Monoamine Oxidase Inhibitors (pharmacology, therapeutic use)
  • Nerve Growth Factors (metabolism)
  • Neuronal Plasticity (drug effects)
  • Neuroprotective Agents
  • Parkinson Disease (drug therapy, genetics, metabolism, psychology)
  • Rats, Sprague-Dawley

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: